Long-Term Use of Tadalafil Linked to Increased Glaucoma Risk in Men

A recent study published in the British Journal of Ophthalmology has highlighted a potential link between long-term use of tadalafil, commonly known as Cialis, and an increased risk of developing glaucoma. This revelation suggests that men using this erectile dysfunction medication to manage urinary symptoms from an enlarged prostate should undergo closer scrutiny regarding their eye health.

Study Overview and Findings

Researchers scrutinized health data from 73,854 men over 40 years old within the TriNetX Analytics Network, comparing the outcomes of two groups: those who had been prescribed tadalafil or another phosphodiesterase type 5 inhibitor (PDE5i) for urinary symptoms and those who had not received these medications. This data spanned from January 2012 to December 2022, with participants on these medications for as long as five years.

The study aimed to determine the incidence of glaucoma and ocular hypertension among these two cohorts. Initial findings revealed that men taking tadalafil presented a striking 22% higher likelihood of developing glaucoma compared to their counterparts who did not use the medication. Furthermore, ocular hypertension appeared 32% more frequently in the tadalafil group, and primary open-angle glaucoma, the most prevalent form of the disease, was reported 33% more often.

Demographic Impact and Limitations

Interestingly, the increased risk of developing glaucoma remained consistent even when analyzing men who experienced the condition shortly after beginning tadalafil treatment—within 1, 3, or 6 months. This trend was notably observed in male participants aged 50 and older as well as among White participants and those with specific underlying health conditions. However, the study's limitations must be acknowledged. Researchers did not track changes in medication use over time nor the emergence of new health issues during the study. Moreover, since most participants were White, the applicability of these findings to diverse populations may be limited.

Implications for Patients

While the findings indicate a significant association between tadalafil use and glaucoma risk, the researchers stress that this does not imply a direct causative relationship. Their study is observational in nature, which allows for the identification of correlations but does not infer causation.

Crucially, researchers recommend that patients, especially those with pre-existing risk factors for glaucoma—such as a family history of the condition or ocular hypertension—should remain vigilant about their eye health. They advocate for regular eye screenings and follow-up appointments for those using tadalafil long term, rather than advising against its usage. The implications of their findings underscore the necessity for baseline ophthalmic assessments in such patients.

As they noted, “These findings do not contraindicate tadalafil use but highlight the importance of baseline ophthalmic assessment and regular follow-up.” Patients at risk, including those with high myopia or requiring long-term therapy, may find that enhanced monitoring could be vital in preserving their vision.

Looking Ahead

Ultimately, these results pave the way for future investigations into how long-term use of PDE5 inhibitors like tadalafil may interact with ocular health. As the medical community continues to explore this relationship, patients and healthcare providers should engage in informed discussions about the risks and benefits of ongoing tadalafil therapy.

Materials supplied by BMJ Group. Note: Content may be edited for style and length.

This Strange New Magnetism Could Change How Computers Work

Scientists Decode a 12,000-Year-Old Mystery Hidden in Ancient Spear Points

Switzerland’s Glaciers Lost More Than 5% of Their Ice in Just One Year

Scientists Tested This Tropical Fruit for Diabetes – and Found an Unexpected Blood Pressure Effect

Stay informed with ScienceDaily's free email newsletter, updated daily and weekly. Or view our many newsfeeds in your RSS reader:

Keep up to date with the latest news from ScienceDaily via social networks:

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?